Clinical Trial Update: Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition [Phase 2]

View source ↗

Summary

Phase 2 trial assessing Vactosertib with Durvalumab for urothelial carcinoma that had progressed on checkpoint inhibitors has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• IMFINZI (DURVALUMAB)
• Vactosertib (Vactosertib)

Snippet

Sponsor: MedPacto, Inc. | Conditions: Urothelial Carcinoma Recurrent, Advanced Urothelial Carcinoma | Phase 2 | Status: WITHDRAWN